Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Selank | Tesamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg daily via intranasal administration (0.15% solution, 2-3 drops per nostril). | Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy). |
| Timing | Can be dosed morning through evening. Unlike Semax, Selank is calming and can be used at night. | Morning administration on empty stomach. Consistent daily timing recommended. |
| Cycle Duration | 14-21 day cycles with equal rest periods. | 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation. |
| Evidence Level | moderate_human | Strong (FDA-approved indication), Moderate (longevity) |
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin (from IgG heavy chain) with a Pro-Gly-Pro extension for metabolic stability. It allosterically modulates GABA-A receptors, enhancing GABA binding and GABAergic neurotransmission. Selank modifies mRNA levels of 84 genes involved in GABAergic neurotransmission in the frontal cortex, enhances enkephalinase inhibition (increasing endogenous enkephalin levels), and modulates serotonergic and noradrenergic systems to produce anxiolytic and nootropic effects.
Research indicates 250-500 mcg daily via intranasal administration (0.15% solution, 2-3 drops per nostril).
Can be dosed morning through evening. Unlike Semax, Selank is calming and can be used at night.
14-21 day cycles with equal rest periods.
Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.
Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).
Morning administration on empty stomach. Consistent daily timing recommended.
26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →